Skip to main content

Overview

Clinical Research

Dr. Wong has published extensively in the field of interventional cardiology with special focus on new device angioplasty, saphenous vein graft intervention, cardiogenic shock, and drug eluting stent. His current clinical research interests include novel drug eluting stent designs, access site and PFO closure devices, percutaneous valve repair, and application of stem cell technology in the treatment of myocardial ischemia. In the past five years, Dr. Wong and his colleagues had participated in multiple US pivotal trials that led to the FDA approval of both drug eluting stents for the treatment of symptomatic obstructive coronary artery disease. Dr. Wong has recently served as the national principal investigation in the ECLIPSE trial which evaluated the safety and efficacy of an extra-vascular bio-degradable access site closure device in patients undergoing coronary or peripheral diagnostic/interventional procedures compare to the standard treatment of manual compression. Other exciting areas of ongoing research include percutaneous treatment valvular disease states including mitral regurgitation and aortic stenosis, assessment of novel pharmacologic agents to enhance safety of angioplasty procedures. His clinical research activities have been published in Journal of American College of Cardiology, American Journal of Cardiology, American heart Journal and he has presented his findings at numerous national and international meetings including American Heart Association, American College of Cardiology, Transcatheter Therapeutics, Summer in Seattle, Taiwan Society of Cardiology and Asia Pacific Cardiology Congress. He is recruited to serve as member of the Scientific Advisory Board of multiple major US medical device companies.

Publications

210 publications

Funding

3 grants
Completed grants (3)
  • Co-I
    Outcomes of Advances in Therapy in Aortic Stenosis
    Michael Wolk Heart Foundation, Inc. · 2017–2020
    MWHFI 17081089-02
  • Co-I
    Hybrid Coronary Revascularization Trial- DCC
    National Heart, Lung, and Blood Institute · 2018–2019 · via Icahn School of Medicine at Mount Sinai
    U01HL125506-03
  • KP
    Rates of Coronary Artery Revascularization and Outcomes After Percutaneous Coronary Interventions and Coronary Artery Bypass
    New York Cardiac Center, Inc. · 2015–2017
    NYCCI 15071021-01

Clinical research

4 studies
Completed & closed trials (4)
  • PI
    A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon (EXPANSE-PTCA)
    NA · Infraredx, Inc. · IRB STUDY CLOSURE (as of 2023)
    Coronary Stenosis; Coronary Artery Stenosis; In-stent Restenosis
    NCT04985773
  • PI
    PeRclose Or Manta Post-TAVR Non-Randomized Registry
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
  • PI
    Early Feasibility Study of the Vivasure PerQseal® Closure Device System After Use of the Impella Device for Cardiogenic Shock or Protected Percutaneous Coronary Intervention
    NA · Vivasure Medical Ltd. · IRB STUDY CLOSURE (as of 2022)
    Percutaneous Large Hole Vascular Closure
    NCT04818541
  • PI
    Treatment of single patient with Tricuspid Regurgitation using the Edwards EVOQUE Tricuspid Valve Replacement System
    Edwards Lifesciences Corp. · IRB STUDY CLOSURE (as of 2022)

Available technologies